Side-by-side · Research reference
BronchogenvsLivagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BAnimal-StrongHUMAN-REVIEWED20/32 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
01Mechanism of Action
Parameter
Bronchogen
Livagen
Primary target
Bronchial epithelial cellsKuzubova 2015
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
Livagen
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Animal dose (oral)
—
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
Duration (experimental)
—
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
Route
—
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
Human data
—
None in provided literature
04Side Effects & Safety
Parameter
Bronchogen
Livagen
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Reported adverse effects
—
None documented in animal studies
Human safety data
—
No human trials in provided literature
05Administration Protocol
Parameter
Bronchogen
Livagen
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
—